Loading...
•
Jun 30
Mink Therapeutics Q2 2025 Earnings Report
MiNK Therapeutics reported clinical and strategic milestones and second quarter 2025 results, highlighting progress in clinical programs, a strengthened balance sheet, and expanded funding.
Key Takeaways
MiNK Therapeutics reported a net loss of $4.2 million for Q2 2025, or $1.06 per share, compared to a net loss of $2.7 million, or $0.73 per share, for Q2 2024. The company ended the quarter with $1.6 million in cash and cash equivalents, with subsequent equity sales raising an additional $13 million, extending its cash runway beyond mid-2026.
MiNK Therapeutics reported a net loss of $4.2 million for Q2 2025, or $1.06 per share.
The company ended Q2 2025 with $1.6 million in cash and cash equivalents, with an additional $13 million raised post-quarter end.
Cash runway has been extended beyond mid-2026 due to strengthened financial position and non-dilutive grants.
Significant clinical progress was highlighted, including durable complete remission in metastatic testicular cancer and advancements in GvHD and gastric cancer studies.
Mink Therapeutics
Mink Therapeutics
Forward Guidance
MiNK Therapeutics anticipates extending its cash runway beyond mid-2026, supported by current cash and recent equity sales. The company plans to advance its clinical programs, including initiating a new clinical trial for AgenT-797 in GvHD in the second half of 2025 and expecting additional clinical readouts from the Phase 2 gastric cancer study in 2025.
Positive Outlook
- Cash runway extended beyond mid-2026.
- Department of Defense STTR Grant awarded for GvHD program.
- New clinical grant awarded to launch AgenT-797 in GvHD clinical trial, targeting initiation in 2H2025.
- Anticipated additional clinical readouts in 2025 for Phase 2 gastric cancer study.
- Strengthened balance sheet through equity sales.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.
- No specific negative forward guidance was provided in the report.